NCRI 2021 | FOCUS4-N: Maintenance capecitabine monotherapy in mCRC

Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, describes the results from the FOCUS4-N trial (EudraCT Number: 2012-005111-12) investigating oral maintenance capecitabine in patients with metastatic colorectal cancer as opposed to capecitabine and bevacizumab, the standard of care, in colorectal cancer. Patients in the FOCUS4-N trial either received capecitabine monotherapy or a treatment break as defined in the COIN trial (NCT00182715). The primary endpoint of progression-free survival (PFS) was met in patients receiving capecitabine. Dr Seligmann additionally discusses whether PFS or overall survival (OS) is the superior primary endpoint in maintenance trials. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.